Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

The condition, called metabolic dysfunction-associated steatohepatitis, or MASH, is a difficult-to-treat disease that affects ...

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...

The doctor explained that beside alcohol consumption and hepatitis, hypertension can contribute significantly to liver fibrosis.

The liver is the body’s chemical factory, where most metabolic processes take place. It processes everything you eat and drink, converting them into energy and essential nutrients. Additionally, the ...

At the moment, Madrigal Pharmaceuticals seems to be in the lead to bring a NASH drug to market, after its daily oral drug resmetirom met primary and secondary objectives in a phase 3 NAFLD trial ...

tool called AIM-NASH in clinical trials to help identify the severity of a type of fatty liver disease. The condition, called metabolic dysfunction-associated steatohepatitis, or MASH, is a ...

NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects millions of people and which, for several years, has been billed as pharma's next big growth area. So far, however ...

It is the progressive form of non-alcoholic fatty liver disease (NAFLD). NASH can lead to cirrhosis and liver cancer. Shumbayawonda et al. examine the impact of multi-parametric MRI in managing ...

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...